Alnylam and MIT Collaborators Publish Data on Novel Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new data describing a novel approach for systemic delivery of RNAi therapeutics using synergistic combinations of novel lipid-like materials called 'lipidoids'.

How nanotechnology will transform disease detection

Conventional diagnostic tools often cannot detect many cancers, Alzheimer's and other life-threatening diseases early enough to provide effective treatment. But nanotechnology, which is revolutionizing electronics and other fields, promises to similarly transform medicine, particularly when it comes to identifying illnesses more quickly.

Physicists break 150-year-old law

A violation of one of the oldest empirical laws of physics has been observed by scientists at the University of Bristol. Their experiments on purple bronze, a metal with unique one-dimensional electronic properties, indicate that it breaks the Wiedemann-Franz Law.

XEI Scientific Launches Evactron CombiClean at M+M 2011

XEI Scientific Inc, manufacturers of more than 1,100 EVACTRON De-Contaminator Plasma Cleaning Systems for electron microscopes and other vacuum chambers, announces the release of their new Evactron CombiClean system which simplifies the control and operation of plasma radical sources for both column and desktop cleaning of specimens for electron columns used in SEMs, TEMs and FIBs.

Nanoparticles working in harmony

A team of researchers from MIT, the Sanford-Burnham Medical Research Institute, and the University of California at San Diego (UCSD) has designed a new type of delivery system in which a first wave of nanoparticles hones in on the tumor, then calls in a much larger second wave that dispenses the cancer drug. This communication between nanoparticles, enabled by the body's own biochemistry, boosted drug delivery to tumors by more than 40-fold in a mouse study.

Polymeric nanoparticles attack head and neck cancer

Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. Now, researchers at the University of Michigan have developed a tumor-targeted nanoparticle that delivers high doses of anticancer agents directly to head and neck tumors.